Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gastrointestinal Cancers
•
Neuroendocrine Tumors
What radiation therapy dose do you recommend for patients with high-grade neuroendocrine carcinoma of the esophagus and/or stomach who undergo chemoradiotherapy?
Related Questions
After R1 resection of a locally advanced, node-positive neuroendocrine tumor of the terminal ilium, would you offer adjuvant radiation therapy?
What are your top takeaways from ASCO GI 2025?
What is your approach to pancreatic adenocarcinoma s/p surgery with N0/R0 disease and intermediate risk factors with regard to adjuvant chemo-radiation?
Would you recommend radiation or chemoradiation in a patient with cholangiocarcinoma s/p surgery and adjuvant treatment with single hepatic metastasis 3 years later?
Is it safe to treat the stomach to a definitive dose if the patient has a G-tube/PEG in place?
Would you offer pelvic re-irradiation in the setting of locally recurrent anal cancer in the presacral region?
What is your approach to TNT sequencing for locally advanced rectal primaries with low volume metastatic disease to liver?
What stomach constraint would you accept in abdominal reirradiation?
How do you manage persistent rectal bleeding in the setting of rectal adenocarcinoma in a treatment-naive patient?
When treating primary liver disease with radiation, how do you contour and constrain the central bile ducts?
